Ipilimumab

Overview

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. WP

Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and boosts the body's immune response against cancer cells.[1][2] WP

Ipilimumab was approved by the US Food and Drug Administration in March 2011, for the treatment of melanoma, renal cell carcinoma (RCC), colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, and esophageal cancer. It is undergoing clinical trials for the treatment of bladder cancer and metastatic hormone-refractory prostate cancer.[3–8] WP⚠ Wikipedia itself has flagged this text: when?.

The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while he was director of the Cancer Research Laboratory at the University of California, Berkeley. Clinical development of anti-CTLA4 was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. For his work in developing ipilimumab, Allison was awarded the Lasker Award in 2015. Allison later was the co-winner of the 2018 Nobel Prize in Physiology or Medicine.[9–12] WP

Uses, dosage and effects

Medical uses

Ipilimumab was approved by the US Food and Drug Administration in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery. It was later approved by the FDA in October 2015, for stage 3 patients as adjuvant therapy. On 1 February 2012, Health Canada approved ipilimumab for "treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease." Ipilimumab was authorized in the European Union (EU), for second line treatment of metastatic melanoma in November 2012.[1][4][13–19] WP

Nivolumab, in combination with ipilimumab is indicated for treating the following: WP

• intermediate or poor risk, previously untreated advanced renal cell carcinoma[20][21] WP
• people aged 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.[20][22] WP
• people with hepatocellular carcinoma who have been previously treated with sorafenib.[20][23] WP
• a first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test.[20][24][25] WP

In October 2020, the FDA approved the combination of nivolumab with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.[26] WP

In April 2025, the FDA approved nivolumab with ipilimumab for people aged 12 years and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. The FDA also converted the accelerated approval to regular approval for single agent nivolumab for people aged 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.[27] WP

Risks and side effects

Adverse effects

A major drawback of ipilimumab therapy is its association with severe and potentially fatal immunological adverse effects due to T cell activation and proliferation, occurring in 10% to 20% of patients. Serious adverse effects include stomach pain, bloating, constipation, diarrhea, fever, trouble breathing, and urinating problems. A "risk evaluation and mitigation strategy" informs prescribers of the potential risks.[15][28][29] WP

Between 5.7% and 9.1% of individuals treated with ipilimumab develop checkpoint inhibitor induced colitis.[30] WP

Individual cases of severe neurologic disorders following ipilimumab have been observed, including acute inflammatory demyelination polyneuropathy and an ascending motor paralysis, and myasthenia gravis.[31] WP

Interactions

Interactions

The combination of ipilimumab with either leflunomide or vemurafenib may lead to increased hepatotoxicity.[20][32][33][34] WP

Pharmacology

Mechanism of action

T lymphocytes can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows the lymphocytes to continue to destroy cancer cells.[2] WP

Cancer cells produce antigens, which the immune system can use to identify them. These antigens are recognized by dendritic cells that present the antigens to cytotoxic T lymphocytes (CTLs) in the lymph nodes. The CTLs recognize the cancer cells by those antigens and destroy them. However, along with the antigens, the dendritic cells present an inhibitory signal. That signal binds to a receptor, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), on the CTL and turns off the cytotoxic reaction. This allows the cancer cells to survive.[2] WP

Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the CTLs to destroy the cancer cells. In 2014 a study indicated that the antibody works by allowing the patients' T cells to target a greater variety of antigens rather than by increasing the number attacking a single antigen.[2][35–41] WP

Pharmacokinetics

The elimination half-life of ipilimumab is about 15 days.[20] WP

History

History

Following the 1987 cloning of CTLA-4 in mice, its conservation in humans and similarities with CD28 were soon noticed. CD28 at that time was a recently identified "T cell costimulatory" molecule important for T cell activation. Anti-CTLA-4 blockade, the invention that gave rise to ipilimumab, was conceived by Allison and Krummel along with CTLA-4's inhibitory role in T cell activation. They were able to demonstrate that CTLA-4 signaling in T cells inhibited T cell responses. They then injected intact antibodies and demonstrated that CTLA-4 blockade enhanced T cell responses in mice responding to vaccines and to super antigens. Leach, a new postdoctoral fellow, was tasked by Allison with applying these in tumor models. Antibody-treated mice showed significantly less cancer growth than the controls.[9][42–47] WP

Bluestone and Linsley separately studied the similarities between CD28 and CTLA-4. Bluestone's lab published studies, one together with Krummel and Allison, for in vitro studies of CTLA-4 function. In collaboration with Mark Jenkins, they were able to see effects of anti-CTLA-4 antibodies in vivo in an immunization setting, but did not effectively carry this into tumor biology. Linsley and colleagues had made antibodies against CTLA-4 three years prior to those of Krummel/Allison or Walunas/Bluestone. They concluded that the molecule functioned similarly to CD28 and was a "positive costimulator". They apparently did not pursue CTLA-4 tumor targeting, although BMS licensed the Allison/Leach/Krummel patent through their acquisition of Medarex and the fully humanized antibody MDX010, which later became ipilimumab.[48–51] WP⚠ A word may be missing here. It reads this way in the source too.

Clinical trial history

In the 2000s, ipilimumab clinical trials were under way on patients with melanoma, renal cell carcinoma, prostate cancers, urothelial carcinoma and ovarian cancer. By 2007, there were two fully human anti CTLA-4 monoclonal antibodies in advanced clinical trials. Ipilimumab, which is an IgG1 isotype, and tremelimumab (from Pfizer) which is an IgG2 isotype.[52–55] WP

Melanoma

In December 2007, Bristol-Myers Squibb and Medarex released the results of three studies on ipilimumab for melanoma. The three studies tested 487 patients with advanced skin cancer. One of the three studies failed to meet its primary goal of shrinking tumors in at least 10.0% of the study's 155 patients. Side effects included rashes, diarrhea, and hepatitis.[56] WP

In 2010, a study was presented that showed a median survival of ten months in advanced melanoma patients treated with ipilimumab, compared with 6.4 months for those treated with gp100, an experimental vaccine (n=676), and 10.1 months for those treated with both the vaccine and ipilimumab. The phase III clinical studies on the drug were controversial for their unconventional use of a control arm (as opposed to using a placebo or standard treatment). Ipilimumab gained FDA approval in March 2011.[4][13][57] WP

Prostate cancer

In 2008/09 Medarex performed a phase I/II dose escalation clinical trial of ipilimumab in metastatic hormone-refractory prostate cancer (HRPC). Some of the patients with advanced prostate cancer had their tumors drastically shrink, promoting further trials.[58] WP

In June 2009, the Mayo Clinic reported two prostate cancer patients involved in a phase II study using MDX-010 therapy who had been told initially that their condition was inoperable but had their tumors shrunk by the drug such that operation was possible and are now cancer-free as a result. This press report was criticized as premature and inaccurate, because the clinical trials were still at an early stage and were run alongside other treatments, which could have been the main reason for the tumor shrinkage. Thus, it was too early to say whether ipilimumab made any difference.[59][60][61] WP

In 2016, a phase II study using ipilimumab and nivolumab in AR-V7-expressing metastatic castration-resistant prostate cancer was opened. AR-V7 is an androgen receptor splice variant that can be detected in circulating tumor cells of metastatic prostate cancer patients.[62][63][64] WP

Lung cancer

CHECKMATE-227 tested the combination of nivolumab and ipilimumab in patients with stage IV or recurrent non-small cell lung cancer (NSCLC) without previous treatment. Patients with a PD-L1 expression level of 1% or more were randomized in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The chemotherapy used was cisplatin or carboplatin, combined with gemcitabine for patient with squamous cell NSCLC, or pemetrexed for patients with nonsquamous disease. The overall survival (OS) was 17.1, 15.7 and 14.9 months, respectively. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. The OS was 17.2, 15.2 and 12.2 months, respectively.[65][66] WP

CHECKMATE-9LA randomized patients with stage IV NSCLC, to nivolumab 360 mg Q3W + ipilimumab 1 mg/kg Q6W + two cycles of chemotherapy or 4 cycles of chemotherapy alone. The chemotherapy used was Cisplatin or Carboplatin combined with Pemetrexed or Paclitaxel. The data were presented in an abstract format and as a lecture during the American Society of Clinical Oncology (ASCO) 2020 annual meeting. Median OS was 15.6 and 10.9 months, in the immunotherapy-chemotherapy and the chemotherapy only groups, respectively.[66][67] WP

Urothelial cancer, including cancer of the bladder, urethra, ureters and renal pelvis

A phase II clinical trial was first reported in 2015. Thirty-six patients were treated with chemotherapy, adding ipilimumab after the second 21-day cycle. Though the study did not meet its primary endpoint, a significant expansion of circulating CD4 cells was noted upon addition of ipilimumab, which correlated with improved survival, especially in patients with deleterious somatic DNA damage response mutations.[68][69] WP

Advanced melanoma

In 2013, a trial was running that compared ipilimumab alone against ipilimumab in combination with nivolumab. The response rate (tumours shrinking by at least 30%) was 58% for the combination, 44% for nivolumab alone, and 19% for ipilimumab alone. This combination gained approval for melanoma by the US Food and Drug Administration in October 2015.[70] WP

In March 2014, an open-label, randomized, two agent, single center trial started combining ipilimumab with phosphatidylserine-targeting immunotherapy bavituximab for the treatment of advanced melanoma. The number of treated patients in arm A (ipilimumab plus bavituximab) was to be 16, with 8 in arm B (ipilimumab only). The trial was terminated in April 2016 due to low enrollment. Previous, preclinical studies showed that PS targeting antibodies (such as bavituximab) enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.[71][72][73] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Syn NL, Teng MW, Mok TS, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. The Lancet. Oncology. December 2017. doi:10.1016/s1470-2045(17)30607-1 · PMID 29208439
2. Journal / agency Ribas A. Tumor immunotherapy directed at PD-1. The New England Journal of Medicine. June 2012. doi:10.1056/nejme1205943 · PMID 22658126
3. Other Yervoy
4. Journal / agency Drug Approval Package: Yervoy (ipilimumab) Injection NDA #125377. 24 December 1999
5. Other Lacroix M. Targeted Therapies in Cancer. 2014
6. Other Pollack A. New Class of Drugs Shows More Promise in Treating Cancer. 29 May 2015
7. Other (completed) ClinicalTrialsGov NCT01524991 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
8. Other (completed) ClinicalTrialsGov NCT00323882 Phase I/II Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (MDX010-21)
9. Journal / agency Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. March 1996. doi:10.1126/science.271.5256.1734 · PMID 8596936
10. Other UC Berkeley Cancer Research Lab » The Story of Yervoy (Ipilimumab)
11. Other Lasker Foundation. Deep brain stimulation for Parkinson's disease
12. Other The Nobel Prize in Physiology or Medicine 2018 to James P. Allison and Tasuku Honjo
13. Journal / agency FDA approves new treatment for a type of late-stage skin cancer. 25 March 2011
14. Other Pollack A. Approval for Drug That Treats Melanoma. 25 March 2011
15. Other Drugs.com: Yervoy
16. Journal / agency FDA approves Yervoy to reduce the risk of melanoma returning after surgery. 28 October 2015
17. Other First an only treatment to extend survival for people with metastatic melanoma, the most deadly form of skin cancer, approved in Canada. 7 February 2012
18. Other Bristol-Myers Squibb Receives Positive Decision from National Institute of Health and Clinical Excellence (NICE) for Yervoy (ipilimumab). 1 November 2012
19. Journal / agency Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F. Metastatic melanoma - a review of current and future treatment options. Acta Dermato-Venereologica. May 2015. doi:10.2340/00015555-2035 · PMID 25520039
20. Journal / agency Yervoy- ipilimumab injection. 13 August 2020
21. Journal / agency FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. 16 April 2018
22. Journal / agency FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer. 10 July 2018
23. Journal / agency FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. 10 March 2020
24. Journal / agency FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%). 15 May 2020
25. Journal / agency FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC. 26 May 2020
26. Journal / agency FDA Approves Drug Combination for Treating Mesothelioma. 2 October 2020
27. Journal / agency FDA approves nivolumab with ipilimumab for colorectal cancer. 8 April 2025
28. Journal / agency Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology. March 2015. doi:10.1177/1758834014567469 · PMID 25755682 · PMC4346215
29. Other FDA Rubber-Stamps Bristol-Myers Squibb's Melanoma mAb. 28 March 2011
30. Journal / agency Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. The American Journal of Gastroenterology. February 2020. doi:10.14309/ajg.0000000000000497 · PMID 31922959
31. Other Two Cases of Myasthenia Gravis Seen With Ipilimumab. 29 April 2014
32. Journal / agency Arava- leflunomide tablet, film coated. 30 October 2024
33. Journal / agency Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England Journal of Medicine. April 2013. doi:10.1056/NEJMc1302338 · PMID 23550685
34. Journal / agency Zelboraf- vemurafenib tablet, film coated. 8 November 2024
35. Journal / agency Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. OncoTargets and Therapy. June 2010. doi:10.2147/ott.s4833 · PMID 20616954 · PMC2895779
36. Journal / agency Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?. The Oncologist. August 2009. doi:10.1634/theoncologist.2009-0028 · PMID 19648604
37. Other Wilkes GM, Barton-Burke M. 2010 oncology nursing drug handbook. 11 December 2009
38. Other Reddy LH, Couvreur P. Macromolecular Anticancer Therapeutics. 1 June 2009
39. Other An Z. Therapeutic Monoclonal Antibodies: From Bench to Clinic. 8 September 2009
40. Other Blum R, Scholz M. Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment Or Loss of Sexual Potency. 24 August 2010
41. Journal / agency Colmone AC. Cancer immunotherapy expands T cell attack. Science. 2014. doi:10.1126/science.345.6203.1463-c
42. Journal / agency Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily--CTLA-4. Nature. Jul 1987. doi:10.1038/328267a0 · PMID 3496540
43. Journal / agency Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. Journal of Immunology. August 1991. doi:10.4049/jimmunol.147.3.1037 · PMID 1713603
44. Journal / agency Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. April 1992. doi:10.1038/356607a0 · PMID 1313950
45. Other Krummel, M.F. (1995). Identification and Characterization of a CTLA-4 Dependent Regulatory Mechanism for T Cell Activation (University of California, Berkeley)
46. Journal / agency Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. August 1995. doi:10.1084/jem.182.2.459 · PMID 7543139 · PMC2192127
47. Journal / agency Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. International Immunology. April 1996. doi:10.1093/intimm/8.4.519 · PMID 8671638
48. Journal / agency Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. The Journal of Experimental Medicine. June 1996. doi:10.1084/jem.183.6.2541 · PMID 8676075 · PMC2192609
49. Journal / agency Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity. August 1994. doi:10.1016/1074-7613(94)90071-x · PMID 7882171
50. Journal / agency Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. Journal of Immunology. August 1995. doi:10.4049/jimmunol.155.3.1032 · PMID 7543510
51. Journal / agency Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. The Journal of Experimental Medicine. December 1992. doi:10.1084/jem.176.6.1595 · PMID 1334116 · PMC2119471
52. Journal / agency Sharma P, Allison JP. The future of immune checkpoint therapy. Science. April 2015. doi:10.1126/science.aaa8172 · PMID 25838373
53. Other CTLA-4 strategies: Abatacept / Belatacept
54. Journal / agency Tomillero A, Moral MA. Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology. October 2008. doi:10.1358/mf.2008.30.5.1236622 · PMID 19088949
55. Journal / agency Poust J. Targeting metastatic melanoma. American Journal of Health-System Pharmacy. December 2008. doi:10.2146/ajhp080461 · PMID 19052265
56. Other Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma. 10 December 2007
57. Journal / agency Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine. August 2010. doi:10.1056/NEJMoa1003466 · PMID 20525992 · PMC3549297
58. Other 'Surprise' prostate result probed. 19 June 2009
59. Other Mayo Researchers: Dramatic Outcomes in Prostate Cancer Study. 1 June 2009
60. Other Boyles S. New Therapy May Fight Prostate Cancer. 19 June 2009
61. Other Lowe D. Medarex, Ipilimumab, Prostate Cancer, And Reality. 23 June 2009
62. Other Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 - Full Text View - ClinicalTrials.gov
63. Journal / agency Silberstein JL, Taylor MN, Antonarakis ES. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. Current Urology Reports. April 2016. doi:10.1007/s11934-016-0584-4 · PMID 26902623 · PMC4888068
64. Journal / agency Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. September 2014. doi:10.1056/NEJMoa1315815 · PMID 25184630 · PMC4201502
65. Journal / agency Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine. November 2019. doi:10.1056/NEJMoa1910231 · PMID 31562796
66. Journal / agency Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals. November 2020. doi:10.3390/ph13110373 · PMID 33171686 · PMC7695295
67. Journal / agency Reck M, Ciuleanu TE, Dols MC, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. Journal of Clinical Oncology. 20 May 2020. doi:10.1200/JCO.2020.38.15_suppl.9501
68. Other Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). - 2015 ASCO Annual Meeting - Abstracts - Meeting Library
69. Journal / agency Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology. May 2018. doi:10.1016/j.eururo.2017.12.001 · PMID 29248319
70. Journal / agency pmhdev. Immunotherapy drug combo could combat melanoma
71. Other Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy) in Advanced Melanoma
72. Other ClinicalTrialsGov NCT01984255 A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
73. Other Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer. 9 April 2014

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.